Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
dc.contributor.author | Hernando, Cubero J | |
dc.contributor.author | Grande, E | |
dc.contributor.author | Gauna, DC | |
dc.contributor.author | Ibrahim, T | |
dc.contributor.author | Fazio, N | |
dc.contributor.author | Lopez, C | |
dc.contributor.author | Teule, A | |
dc.contributor.author | Valle, Juan W | |
dc.contributor.author | Alonso, V | |
dc.contributor.author | Molina-Cerrillo, J | |
dc.contributor.author | Tafuto, S | |
dc.contributor.author | Custodio, A | |
dc.contributor.author | Trejo, L | |
dc.contributor.author | Casteras, A | |
dc.contributor.author | Kopp, RM | |
dc.contributor.author | Miqueo, C | |
dc.contributor.author | Herrera, MR | |
dc.contributor.author | Garcia-Carbonero, R | |
dc.contributor.author | Salazar, R | |
dc.contributor.author | Capdevila, J | |
dc.date.accessioned | 2019-12-09T17:23:31Z | |
dc.date.available | 2019-12-09T17:23:31Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Hernando Cubero J, Grande E, Castellano Gauna D, Ibrahim T, Fazio N, Lopez C, et al. 1387P Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs). Annals of Oncology. 2019;30(Supplement_5):567. | en |
dc.identifier.doi | 10.1093/annonc/mdz256.007 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622592 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdz256.007 | en |
dc.title | Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Medical Oncology, Vall d'Hebron University Hospital, Barcelona | en |
dc.identifier.journal | Annals of Oncology | en |
refterms.dateFOA | 2020-01-21T20:13:01Z |